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ABSTRACT 
 
Src signaling plays an important role in prostate cancer (PrCa) progression.  It has 
previously been shown that Src interacts with androgen receptor (AR) and enhances AR 
transactivation.  Although it has been shown that Src promotes AR activity, the underlying 
pathway has not been defined.   
To help characterize the Src-AR pathway, the cellular localizations of Src, p-Src, AR, 
pAR, and Prostate Specific Antigen (PSA, an AR target gene) were analyzed in androgen-
dependent (AD) LNCaP cells and in androgen-independent (AI) castration-resistant C4-2B cells.  
Using sub-cellular fractionation, the data showed that treatment of AD cells with synthetic 
androgen R1881 increased p-Src, AR, pAR, and PSA in the nucleus, while the levels of c-Src 
remained unchanged.  Treatment of AI cells with R1881 increased pSrc and AR in the nucleus, 
while the levels of c-Src and PSA remained unchanged.  When using Immunofluorescence 
microscopy, R1881 did not appear to increase the nuclear levels of p-Src or c-Src, so perhaps this 
technique is not as sensitive or quantitative as sub-cellular fractionation/immunoblots. 
The presence of PSA in the nucleus was unexpected given its well-proven role as a 
secreted protein.  Nuclear PSA was observed upon androgen stimulation in AD and AI cells, and 
in the nucleus of AI cells upon androgen deprivation.  Given PSA’s ability to induce cell division 
and decrease apoptosis when transfected into cells, its presence in the nucleus may imply that 
PSA acts there to help induce tumorigenesis.  
The effect of Src on AR activity was further studied by transfection of a dominant 
negative src (SrcK298M) in AD and AI cells.  Transfection with SrcK298M did not affect PSA 
expression in LNCaP cells, but strongly inhibited PSA levels in AI cells.  
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Integrin signaling through Src was investigated in PrCa by ligand binding assay in AD 
and AI cells.  The data showed that αvβ3 integrin (but not αvβ6) upon attachment to fibronectin 
or   TGFβ-latency associated peptide (TGFβ-LAP) increases p-Src levels in AD and AI cells, 
while the levels of c-Src, PSA, and AKT remain unchanged.  Thus, αvβ3 integrin facilitates Src 
signaling, but the activation does not appear to affect AR transactivation.   
In conclusion, these data show that Src is required for AR activity and, consequently, 
PSA expression in AI prostate cancer cells, but not in AD cells.  These data also suggest that the 
nuclear co-localization of p-Src, AR and PSA might allow macromolecular interactions, which 
can further enhance AR transactivation and promote disease progression.  With respect to the 
switch in tumor progression from an AD to AI state, the data indicate that the integrin-Src 
pathway does not include AKT or PSA (and not AR by deduction), so perhaps other non-AR 
pathways help facilitate tumor growth at the AI state.  
 4 
TABLE OF CONTENTS 
 
ABSTRACT............................................................................................................ 2  
 
TABLE OF CONTENTS........................................................................................ 4  
 
LIST OF FIGURES................................................................................................. 5  
 
ACKNOWLEDGEMENTS.................................................................................... 6  
 
THESIS PURPOSE................................................................................................. 7  
 
BACKGROUND.................................................................................................... 8 
 
MATERIALS AND METHODS........................................................................... 22 
 
RESULTS.............................................................................................................. 27  
  
DISCUSSION....................................................................................................... 40 
 
OVERALL CONCLUSIONS……………………………………….…..……… 44 
 
FUTURE EXPERIMENTS…………………………………………….……….. 44 
 
BIBLIOGRAPHY................................................................................................. 46 
 
 5 
 
LIST OF FIGURES  
 
Table 1: Cancer Statistics 2009…...……………………………………………….……………8 
Figure 1: Androgen-Independent Pathways………………………………………….………..10 
Figure 2: Androgen Receptor Activation……………………...........................………………12 
Figure 3: Androgen receptor gene……………………………………………………………..13 
Figure 4: Integrins and their signaling in prostate cancer………………………………..……15 
Figure 5: Src gene and structure………………………………………………………...….....17 
Figure 6: Src Activation…………………………………………………………………….....18 
Figure 7: Src activation and function…………………………….…………………………....19 
Figure 8:  AR nuclear localization upon R1881 stimulation………………………………….28 
Figure 9:  AR has a dynamic trafficking system……………………………….…….……….29 
Figure 10:  p-Src localizes in the nucleus and androgen does not affect Src localization….....30 
 Figure 11:  Nuclear localization of Src and AR…………………………….……..………….32 
Figure 12:  AR and PSA nuclear translocation………………………………………………..34 
Figure 13: Src differentially affects AR activity in AD and AI PrCa cells……….………......35 
Figure 14:  αvβ3 integrin increases Src activation…………………………………………….37 
Figure 15: αvβ3 integrin does not affect PSA expression levels…………..…………………39 
 6 
 
ACKNOWLEDGEMENTS 
 
I take this opportunity to thank my advisor Dr. Lucia R. Languino (UMass Medical 
School) for all her support and guidance throughout the research process.  It was her continuous 
motivation, and her ability to bring out the best of me, that led to the successful completion of 
this thesis. 
I would also like to extend my gratitude to my committee members Dr.Samuel Politz and 
Dr. Dave Adams, and the Biology & Biotechnology Department, WPI for their approval to work 
with Dr. Languino, and for their valuable advice.   
I would like to thank Dr. Tao Wang for his constant effort, interest in my project and for 
providing unique insights into the development of this project.  He has gone above and beyond in 
helping me complete and learn from this work, and I greatly appreciate the time and effort he has 
put in to make this experience possible for me.  
I would like to thank Dr. Hira Lal Goel, Dr. Jing Li, and Dr. Marco Trerotola for their 
constant encouragement, technical help, and for making this experience both enjoyable and 
educational for me. 
I would also like to thank Dr. Swarna Mehrotra and Dr.Dario Alteri lab for their generous 
donation of time and materials related to the project. 
I would also like to extend my gratitude to Heather Ehlers and Alana Calpai 
administrative assistants in the Cancer Biology department (UMass), and Carol Butler 
administrative assistant in the Biology and Biotechnology department (WPI) for their help in 
arranging committee meetings. 
Lastly, I would like to thank my family and friends for their continuous support and 
encouragement, which kept me going during difficult times. 
 7 
THESIS PURPOSE 
 
 It has previously been shown that Src phosphorylates and activates AR in AI PrCa cells 
(Guo et al., 2006).  Hence, it can be hypothesized that Src plays an important role in PrCa 
disease progression.   Src activation promotes AR nuclear translocation and promotes AR 
transactivation.  However, the mechanism of Src-regulated AR activity in PrCa remains to be 
explored.  It is also known that cytoplasmic domains of integrins interact with Src and results in 
Src activation.  Thus, this integrin-Src pathway may help regulate AR activity.  
 The first and second part of this thesis focused on the role of Src in the regulation of AR 
activity in PrCa.  Src activity is known to be important in PrCa since tumors in which Src 
activity has been blocked show reduced tumor volume (Recchia et al., 2003).  Since AR is found 
to be localized in the nucleus upon ligand binding, and increased Src kinase activity is found in 
PrCa tumor xenografts, I studied AR, Src, and PSA localization in PrCa cells upon stimulation 
with synthetic androgen R1881.  Then, I studied the effect of Src expression and phosphorylation 
on AR activity in LNCaP (AD) and C4-2B (AI) PrCa cell lines.  And finally, I analyzed the role 
of an integrin-Src-AR pathway on the localization of Src, p-Src, AR, p-AR, and PSA. 
Therefore, this thesis investigated novel mechanisms, which modulate AR activity by 
studying Src localization, expression and phosphorylation in androgen-dependent and 
independent cell lines, and the potential ability of integrins to activate this pathway.  
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BACKGROUND 
 
Prostate cancer is the second leading cause of cancer death among men in Western 
countries.  In 2010, 192,280 new cases, and 27,360 estimated deaths are predicted to occur due 
to PrCa in United States (Jemal et al., 2009) (Table 1).  Patients with advanced PrCa initially 
benefit from androgen-ablation therapy, which leads to temporary tumor remission due to 
apoptosis of androgen-sensitive tumor cells.  However, the recurrence of AI tumors is inevitable 
for most patients, and renders the conventional hormone ablation therapy ineffective (Feldman 
and Feldman, 2001; Debes and Tindall, 2004).  It has, therefore, become a focus of intensive 
study to understand the mechanisms underlying the development of hormone-refractory PrCa.  
 
Table 1: Cancer Statistics 2009 (Jemal et al., 2009). 
 
 
 
 9 
Androgen-Independent Prostate Cancer 
 Prostate cancer develops in the prostate gland, and the tumor cells can metastasize from 
prostate to other parts of the body, such as lymph nodes and bones.  Disease diagnosis involves 
screening prostate specific antigen (PSA) levels present in serum.  PSA is a member of the 
human kallikrein family of serine proteases (Heinlein and Chang, 2004).  PSA is secreted by the 
prostate gland, and is found in small quantities in normal patients.  It is a 33kDa, human 
kallikrein gene family member, and a serine protease that inhibits coagulation of the seminal 
fluid (Balk et al., 2003).  The major substrates of PSA are seminogelin I and II that mediate gel 
formation in the semen (Balk et al, 2003).  Other PSA substrates include fibronectin, TGFβ, 
PTH-related peptide, and plasminogen (Yousef et al., 2001).  PSA was initially detected in the 
cytoplasmic vesicles and secretory granules of epithelial cells (Sinha et al., 1987).  Serum PSA 
levels are often elevated in PrCa disease.  PSA is a one of the major AR-dependent target genes, 
and is clinically monitored to detect early stage disease and the emergence of recurrent tumors 
post-therapy (Nash and Melezinek, 2000; Ryan et al., 2006).  Thus, readouts of AR activity are 
critical for the assessment of disease progression and therapeutic outcome.  PrCa initially 
presents as an AD disease, therefore hormone ablation therapy is often used.  However, the 
disease progresses to a state where it becomes AI.  In these cases the AR becomes hypersensitive 
and responds to very low levels of androgens.  There are five different proposed pathways, 
hypersensitive pathway, promiscuous pathway, outlaw receptor pathway, bypass pathway, and 
lurker pathway, which can lead to AI PrCa (Feldman and Feldman, 2001).  In the hypersensitive 
pathway, AR becomes hypersensitive to low levels of androgens (Fig 1).  The factors that might 
contribute to hypersensitivity include mutations in the AR gene, or increased levels of co-
activators. In the promiscuous pathway, the specificity of AR broadens due to the production of 
 10 
other steroid hormones or even AR antagonists that can activate AR.  In the outlaw pathway, 
there is production of outlaw receptors by crosstalk with growth factor signaling pathways, 
which can phosphorylate and activate AR.  Unlike the three pathways discussed above, the 
bypass pathway is independent of AR.  In this pathway, the pro-apoptotic mechanisms that are 
normally blocked by androgen are, instead, inhibited by a parallel mechanism such as the up-
regulation of Bcl2.  In the lurker cell pathway, AI PrCa cells are lurking in the normal prostate 
and  become selected for by therapy (Fig 1). 
 
 
 
 
      
 
 
 
 
Figure 1: Androgen-Independent Pathways in Prostate Cancer.  Five different 
pathways have been proposed to result in androgen-independent prostate cancer: 
hypersensitive pathway, promiscuous pathway, outlaw receptor pathway, bypass 
pathway, and lurker pathway (Feldman and Feldman, 2001).   
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By understanding the mechanism behind AI PrCa, specific therapies could be designed to 
target the cause behind this disease. 
 
Androgen Receptor 
AR plays a central role in PrCa development and disease progression.  AR, is a member 
of the steroid hormone receptor family which is primarily responsible for mediating the 
physiological effects of androgens by binding to specific DNA sequences, known as androgen 
response elements (AREs) (Heinlein and Chang, 2004).  AR, also known as NR3C4 (nuclear 
receptor subfamily 3, group C, member 4), is a type of nuclear receptor, which is activated by 
binding of either of the androgenic hormones testosterone or dihydrotestosterone (Roy et al., 
2001).  The AR gene is located on the X chromosome at Xq11-12 (Roy et al., 2001).  The main 
function of the AR is as a DNA-binding transcription factor, which regulates gene expression.  
AR appears to be involved in various aspects of the disease, from its commencement to the 
development of treatment resistance.  
In the absence of androgens, AR usually stays in the cytoplasm in an inactive form.  
Upon androgen binding the AR, the AR forms a dimer, which moves from the cytoplasm to the 
nucleus (Roy et al., 2001; Marcelli et al., 2006) (Fig 2).  The nuclear translocation of AR results 
in the binding of AR to ARE’s in the regulatory region of target genes as a transcription factor 
(Heinlein and Chang, 2004).  
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Figure 2: Androgen Receptor Activation. The unliganded AR localizes in the 
cytoplasm as a heteromeric complex with heat shock proteins (Hsp).  Upon androgen 
binding, the AR undergoes conformational changes, gets dimerized and moves from the 
cytoplasm to the nucleus.  The nuclear translocation of AR results in the binding of AR to 
androgen response elements in the regulatory region of target genes as a transcription 
factor (Feldman and Feldman, 2001). 
 
The AR gene is composed of three domains: N terminal domain (NTD), DNA binding 
domain (DBD) and a C-terminal domain or ligand-binding domain (LBD) (Fig 3).  
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Figure 3: Androgen Receptor Gene.  The AR gene is composed of three domains: N 
terminal domain (NTD), DNA binding domain (DBD) and a C-terminal domain or 
ligand-binding domain (LBD) (Litvinov et al., 2003).   
 
 The NTD and LBD domains contain the sub-domains called activation function-1 (AF-
1), and activation function-2 (AF-2), respectively (Litvinov et al., 2003).  AF-1 and AF-2 interact 
with several other co-factors that lead to transactivation of AR.  AF-1 and AF-2 docking sites 
specifically recognize motifs like LXXLL and FXXLF which are present in different co-factors 
(van de Wijngaart et al., 2006).  The FXXLF motif is also present in the NTD that interacts with 
the LBD of AR, although the function of this interaction is not clear.  FXXMF is the common 
motif found in PAK6 and Supervillin.  FXXLF is frequently found in ARA50 and ARA70 
(Miyamoto et al., 1998), while the FXXFF motif is frequently found in Gelsolin, cdc37 (van de 
Wijngaart et al., 2006).  These interactions of the AR with co-factors result in either 
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phosphorylation or dephosphorylation of AR that may cause either activation or inactivation, 
respectively, of AR in PrCa. 
 
AR and Androgen-Independent PrCa 
Activation of the AR plays a role in AI PrCa. Multiple mechanisms including stimulation 
by tyrosine kinases have been postulated. Several phosphorylation sites exist in the AR protein.  
Three tyrosine sites have been studied so far: tyr-267, tyr-363 and tyr-534 (Guo et al., 2006; 
Mahajan et al., 2007).  It was found that the tyr-534 site was evolutionally conserved, which 
suggested that tyr-534 might be of functional importance in hormone refractory cancer (Guo et 
al, 2006).  A mutation at tyr-534 diminished Src-induced tyrosine phosphorylation of AR (Guo et 
al., 2006).  Hormone-refractory tumor lysates were blotted with anti-pAR (Y534) antibody, and 
an increase in pAR expression levels was found in AI tumors as compared to hormone naïve 
tumors.  It was also reported that tyrosine phosphorylation regulates AR nuclear translocation 
and transcriptional activity (Guo et al., 2006).  Hence, it can be hypothesized that AR tyrosine 
phosphorylation has a role in the progression of PrCa to the AI state. 
 
Integrins and Prostate Cancer 
Integrins have been found to play a major role in PrCa progression (Goel et al., 2008).  
Integrins play an important role in cell signaling.  They are crucial regulators of differentiation, 
growth, survival, migration and invasion.  The adhesive contacts between cells and the extra 
cellular matrix (ECM) are mediated by integrins (Fornaro et al., 2003).   They are also involved 
in tumor growth and metastasis. Integrins are dimers of alpha and beta subunits (Fig 4).  Twenty 
four unique integrin dimers can form through different combinations of alpha and beta subunits.  
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αIIb, α6, β1, β3 and β6 integrin subunits are up-regulated in PrCa, while αv, α7, α3 β1C, β4 
integrins are down-regulated (Goel et al., 2008).  
 
Figure 4: Integrins link extracellular matrix 
proteins to the cytoskeleton  (Goel and 
Languino, 2004). 
 
The integrin αvβ6 is neo-expressed in many carcinomas, such as colon (Agrez et al., 
1994), breast (Arihiro et al., 2000), oral squamous carcinoma (Jones et al., 1997), ovarian cancer 
(Ahmed et al., 2002), and in vitro studies suggest that αvβ6 promotes epithelial cell spreading, 
migration, and proliferation (Breuss et al., 1995).  siRNA-mediated down-regulation of AR in 
αvβ6 integrin expressing LNCaP cells shows a strong inhibition of PSA expression levels (Wang 
et al., unpublished data), suggesting that αvβ6 integrin mediates specific pathways that are AR 
dependent, and contributes to increased AR transcriptional activity.  Immunofluorescence studies 
in LNCaP cells expressing αvβ6 integrin showed that AR was localized in the nucleus, even 
under starvation conditions (Wang et al., unpublished data).  This suggests that αvβ6  integrin 
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promotes AR translocation and transcriptional activity via an AI mechanism. 
Integrins promote a wide range of adhesion-dependent effects, including proliferation, 
survival, migration or invasion.  In particular αvβ3 integrin is associated with the progression of 
a variety of human tumors, including melanomas and carcinomas of the prostate, breast, cervix 
and pancreas.  It enhances tumor cell migration, survival and increased growth factor release.  It 
has been previously shown that αvβ3 integrin strongly supports Src-mediated oncogenic 
transformation through an interaction at the β3 cytoplasmic tail (Huvneers et al., 2007).  Src 
phosphorylates αvβ3 integrin, but this phosphorylation is not required for αvβ3 integrin-
mediated support for tumor formation (Huvneers et al., 2007). 
  Thus, integrins regulate Src-mediated oncogenic transformation and various aspects of 
morphological transformation through different pathways.  It has also been reported that αvβ3 
integrin promotes anchorage-independence through Src mediated pathways (Desgrosellier et al., 
2009).  Hence, to define the integrin-Src pathway involved in PrCa disease progression will be of 
utmost importance.  
 
Src Regulation of AR  
Src and its function in cellular mechanisms 
 Src is a non-receptor tyrosine kinase originally discovered in the 1970s (Martin, 2001).  It 
is a 60 kDa protein that consists of three domains, an N-terminal SH3 domain, a central SH2 
domain and a tyrosine kinase domain (Martin, 2001) (Fig 5).  The Src kinase family is comprised 
of nine members:  Src, Lyn, Fyn, Yes, Lck, Hck, Blk, Fgr and Yrk (Fizazi, 2007).    
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Figure 5: Src Gene and Structure. a) The v-Src and c-Src genes.  The v-Src gene 
(bottom) lacks the introns present in c-Src (top), and in v-src the 3'-terminal sequence of 
c-Src is replaced by a downstream sequence. In addition, several activating point 
mutations are present within v-Src (not shown).  A non-defective Rous sarcoma virus 
strain, such as that shown, contains the viral structural genes (gag, pol and env), plus the 
viral-transforming gene, v-Src.  The Bryan strain is replication-defective and lacks a 
functional env gene; some variants of the Bryan strain are also defective in pol. b) 
Structural features of c-Src and v-Src proteins.  Residue numbers and other details are 
specific to chicken c-Src and the v-Src protein of the Schmidt–Ruppin strain of RSV. The 
amino terminus of the protein is myristoylated at Gly2.  Positions of the membrane-
binding (M), unique (U), SH2, SH3, linker (L), catalytic and regulatory (R) domains of c-
Src are shown; the substituted carboxy-terminal sequences in v-Src are shown in red. 
Asterisks represent amino acid substitutions in v-Src (Martin, 2001). 
 
Auto-inhibition of the Src kinase domain results from the interactions between SH2 (Src 
Homology domain 2) and SH3 (Src Homology domain 3) domains.  Auto-phosphorylation at tyr-
416, and de-phosphorylation at tyr-527, are required for activation of c-Src (Cooper et al., 1986).  
Csk (Carboxy-terminal Src kinase) phosphorylates at site tyr527, which results in inactivation of 
c-Src (Okada and Nakawaga, 1989).  Phosphorylation at site tyr-527 was found to be the key 
event in regulating c-Src kinase activity.  Deletion of this site could account for the oncogenic 
activation of Src, and this variant is referred to as v-Src (Martin, 2001) (Fig 6).   
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Figure 6: Src Activation.  Src protein consists of three domains, an N-terminal SH3 
domain, a central SH2 domain and a tyrosine kinase domain.  Auto-inhibition of the 
kinase domain results from the interactions between SH2 and SH3 domains.  Auto-
phosphorylation at tyrosine 416 and dephosphorylation at tyrosine 527 are required for 
activation of c-Src.  Deletion of Tyr527 accounts for the oncogenic activation of Src and 
the variant is referred to as v-Src (Martin, 2001).  
 
Src has been found to be involved in the control of many functions, including cell 
adhesion, growth, movement and differentiation (Dehm and Bonham 2004).  Src can be activated 
by different surface receptors, like receptor tyrosine kinase, G-protein coupled receptor, and 
integrins (Martin, 2001).  Growth factors like PDGF (platelet derived growth factor) activate c-
Src by recruiting it to surface receptors like PDGFR which results in further downstream 
intracellular signaling (Ralston and Bishop, 1985; Kypta et al., 1990) (Fig 7).  
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Figure 7: Src Activation and Function. Src can be activated by different surface 
receptors, like receptor tyrosine kinase, G-protein coupled receptor, and integrins. Src 
signaling is found to be involved in the control of many functions including cell 
adhesion, growth, movement, and differentiation (Martin, 2001). 
 
Many substrates of src have been characterized.  Several of these Src substrates, 
including FAK (focal adhesion kinase) (Lipfert et al., 1992), Cas (Crk and Src associated 
substrate) (Sakai et al., 1994), and Stat3 (Turkson et al., 1998) were found to be important for 
integrin signaling and growth regulation.  Src was also found to play a role in mitogenesis, as it 
is found to be involved in the MAPK and PI3K-mTOR pathways (Penuel and Martin, 1999).  Src 
activity is up-regulated in lung, colon, breast, prostate and pancreatic cancer (Dehm and 
Bonham, 2004).  Hence, Src can play an important role in PrCa disease progression. 
 
Src and Prostate Cancer 
Multiple studies have supported a role for Src tyrosine kinase and its family members in 
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PrCa  (reviewed in Fizazi, 2007).  Src may contribute to AI-PrCa by mediating signals from 
various factors, including growth factors and chemokines (Lee et al., 2004).  It has been reported 
that Src may be involved in the initial transition from an AD to AI state (Lee et al., 2001; Unni et 
al., 2004).  Several studies show that inhibition of Src signaling decreases proliferation, invasion 
and migration of PrCa cells that have detached from the primary site (Recchia et al., 2003), 
suggesting involvement of Src in PrCa progression.  It was found that Src kinase activity gets up-
regulated in androgen refractory PrCa (Guo et al., 2006).  Tumor lysates from hormone 
refractory prostate xenograft models were studied, and it was found that there were high 
expression levels of p-Src in hormone-refractory prostate xenograft tumors compared to their 
hormone sensitive counterparts (Guo et al., 2006).  Studies were also done in human prostate 
tissue samples from hormone-naïve and hormone-refractory patients.  This may suggest a 
possible role of Src in AI-PrCa.  Increased Src expression was also found in TRAMP mouse 
models of PrCa (Asim et al., 2008).  Together, these studies confirm a crucial role of Src in PrCa 
disease and its progression. 
 
Src and its potential role in integrin-mediated signaling 
A signaling partnership is reported among integrins, Src, and FAK, which subsequently 
can result in recruitment of proteins containing SH2 domains to trigger adhesion-induced cellular 
responses (Hanks and Polte, 1996).  FAK phosphorylation at tyr-397 mediates a direct 
interaction with the Src SH2 domain, which results in activation of Src (Hanks and Polte, 1996). 
Recently it has been shown that αvβ3 integrin mediates anchorage-independence and tumor cell 
malignancy in a Src-dependent manner (Desgrosellie et al., 2009).  In breast cancer, α6β4 
integrin was found to promote cancer cell-motility and invasion through a mechanism involving 
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Src, AKT and NFAT (Kim et al., 2009).  Hence, Src tyrosine kinase is found to play a significant 
role in integrin-mediated signaling through indirect association with integrins in cancer 
progression and metastasis. 
 
Src phosphorylation activates AR 
Src interacts and phosphorylates AR at its tyr-534 site (Guo et al., 2006; Kraus et al., 
2006), which is responsible for AR activation.  By transfecting PrCa cell lines with kinase active 
(SrcY527F) and dominant-negative (SrcK295M) constructs, luciferase activity was studied using 
a PSA-luc promoter.  It was found that SrcY527F induced the activity of the PSA promoter, 
suggesting that Src may directly modulate AR transcriptional activity (Guo et al., 2006).  
Specific Src inhibitor SU6656 reduced the AR-driven luciferase activity (Guo et al., 2006).  
Hence, this suggests that Src interaction with AR results in AR activation.  
Though it has been shown that Src-induced phosphorylation regulates the translocation of 
AR from the cytoplasm to the nucleus, it is still unclear how tyrosine kinase phosphorylation of 
AR induces its translocation (Guo et al., 2006).  It is possible that phosphorylation may induce 
conformational changes in the ligand-binding domain of AR, and therefore, even in the presence 
of very low levels of androgen (as in androgen refractory cancer), the androgen responsive genes 
are activated and AR transcriptional activity takes place.  
Understanding the mechanism behind AI PrCa will help in building a novel and effective 
strategy to inhibit PrCa growth and metastasis. 
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MATERIALS AND METHODS 
 
Reagents  
 Synthetic androgen R1881 was obtained from Perkin-Elmer.  The following rabbit 
polyclonal antibodies (pAbs) were used for immunoblotting: pSer81-AR (Dr. Daniel Gioeli), p-
Src (Y416, Cell Signaling), AKT1/2/3 (H-136), ERK1 (C16, Santa Cruz), PSA (DAKO 
Cytomation), and goat polyclonal RCC1 (Santa Cruz).  The following mouse monoclonal 
antibodies (mAbs) were used against androgen receptor (AR) (AR441, Santa Cruz), c-Src (Santa 
Cruz and Cell Signaling), and α-tubulin (DM1A, Sigma) for immunoblotting.  Purified non-
immune mouse IgGs (mIgG) and rabbit IgGs (rIgG) (Pierce) were used as negative controls.  For 
immunofluorescence, rabbit pAb AR (N20, Santa Cruz), p-Src (stimulatory site Y416, Cell 
Signaling), and mAb for c-Src (Santa Cruz) were used.  HRP-conjugated secondary antibodies to 
mouse, rabbit (Cell Signaling) and goat (Santa Cruz) were used for immunoblotting.  Rhodamine 
and fluorescein-conjugated secondary antibodies used for immunofluorescence were purchased 
from Jackson Laboratories.  4', 6-diamidino-2-phenylindole (DAPI) used for 
immunofluorescence was obtained from Molecular Probes, Invitrogen. 
 
Androgen Deprivation and Androgen Stimulation 
 Androgen Deprivation:  Cells were cultured in media containing 2% charcoal stripped 
serum (CSS) for 24 hrs.  This serum was prepared by treating fetal bovine serum (FBS) with 
HCl-treated charcoal.  This medium does not have detectable levels of androgens or steroids that 
might activate AR (based on our laboratory’s internal standard data).  
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 Androgen Stimulation:  Cells were cultured in media containing 2% CSS for 24 hrs, and 
then stimulated with R1881 (1 nM) for 2 hrs or 24 hrs depending upon the experimental 
conditions. 
 
Cells and Culture Conditions 
 LNCaP (AD) and C4-2B (AI) cells were obtained from ATCC.  Cells stably transfected 
with either αvβ3 or αvβ6 integrin genes were obtained from Zheng et al. (1999) and Manes et al.  
(2003).  Cells were cultured in RPMI (GIBCO, Invitrogen) supplemented with 5% FBS (Gemini 
Bioproducts Inc.), 2 mmol/L glutamine, 100 µg/ml streptomycin-100U/ml penicillin, 0.1 mmol/L 
nonessential amino acids and 1 mmol/L sodium pyruvate (GIBCO, Invitrogen).  RPMI 
supplemented with 2% CSS was used for starvation of the cells.  For transient transfection 
experiments, cells were transfected with wild-type Src (wt-src) or dominant negative Src 
(SrcK298M) using Lipofectamine 2000 (Invitrogen), according to the manufacturer’s 
instructions. 
 
Sub-Cellular Fractionation  
 A total of 3x106 cells were trypsinized, and the pellet was washed once with 1XPBS.  
The pellet was resuspended in Buffer A (10 mM HEPES at pH 7.9, 10 mM KCL, 1.5 mM 
MgCl2, 0.34 M sucrose, 10% glycerol, 1 mM DTT, 10 mM NaF, 1 mM Na2VO3, 0.1% Triton X-
100, protease inhibitors, 0.2 mM PMSF), vortexed and kept on ice for 30 min.  Cell homogenate 
was spun at 3,300 RPM for 15 min at 4oC using a microcentrifuge.  The supernatant obtained 
from the above step was removed and stored as cytosolic extract.   
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 The cytosolic extract can be further clarified by centrifuging at 16,000 RPM, to remove 
any contaminants.  The pellet obtained (nuclear fraction) was incubated in an equivalent volume 
of buffer B (3 mM EDTA, 0.2 mM EGTA, 1 mM DTT, 0.2 mM PMSF, and protease inhibitors) 
for 30 min, and centrifuged at 13,000 RPM for 15 mins to remove contaminants such as 
chromatin and nuclei.  The supernatant obtained from the above centrifugation was stored as the 
“nuclear fraction”.  Note: All steps were performed under ice-cold conditions i.e. at 4oC (Zou et 
al., 2002). 
 
Immunoblotting 
 The protein concentration for each cell lysate was quantified with a BCA protein assay 
kit (Pierce) to allow equal loading on the gel.  Proteins were separated by denaturing SDS-
Polyacrylamide Gel Electrophoresis, then transferred to PVDF membrane (Millipore).  
Membranes were blocked for 3 hrs with 5% nonfat dry milk-TBST or 5% bovine serum albumin 
(BSA)-TBST buffer.  Primary antibodies were diluted in blocking buffer according to the 
manufacturer’s protocols, and subsequently incubated with the blots for 2 hr at room 
temperature, or overnight at 4°C.  Primary antibodies against pSer81-AR, p-Src, and c-Src were 
diluted in 5% BSA-TBST buffer.  The membranes were washed three times with TBST and 
incubated with a 1:2000 dilution of the appropriate horseradish peroxidase-conjugated anti-
mouse, anti-rabbit, or anti-goat IgG in the blocking buffer for 2 hr at room temperature.  After 
washing, the blots were developed with enhanced chemiluminescence (Boston Bioproducts) and 
exposed to BioMax X-ray film (ISC Bioexpress) (Fornaro et al., 1998; Goel et al., 2004).  
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Immunofluorescence 
 Cells were grown on cover-slips coated with poly-L-lysine (1 mg/ml) in RPMI 
supplemented with 5% FBS.  After starvation for 24 hrs in RPMI containing 2% CSS medium, 
cells were grown in the presence of ethanol (EtOH) or R1881 (1 nM or 0.1 nM) for 2 hrs.  Cells 
were fixed in 4% paraformaldehyde for 5 min, and washed twice with phosphate buffer saline 
(1X PBS).  The cells were permeabilized with 1X PBS containing 0.2% Triton-X100, and 
blocked with 5% BSA in 1X PBS for 1 hr at room temperature.  Cells were incubated with 
primary antibodies diluted in 5% BSA-PBS buffer for 1 hr at room temperature.  After washing 
with 1X PBS, the cover-slips were incubated with goat anti-rabbit rhodamine or anti-mouse 
fluorescein-conjugated secondary antibody for 1 hr at room temperature.  Cells were washed 
twice for 5 min each with 1X PBS.  Finally, the cells were counterstained with DAPI to visualize 
nuclei before mounting.  The slides were visualized using an Olympus IX71 inverted microscope 
with IPLab V3.55 (Scanalytics, Inc, Rockville, MD), magnification 400X. 
 
Cell Adhesion Assay 
 Cell adhesion assays have been described previously (Zheng et al., 1999). Stable 
transfected αvβ6-LNCaP and αvβ3-LNCaP cells were starved overnight in a serum free RPMI 
culture medium.  Cells were seeded on the culture plates coated with FN (3 mg/ml), LAP-TGF-β 
(0.5 mg/ml) or BSA.  Cells (106) were plated on the substrate for 1 hr in serum-free RPMI 
medium before collecting cell lysates.   
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Small Interfering RNA Transfection 
 LNCaP cells were transfected with β1A and β1C integrin siRNA duplexes (IDT Inc.).  
The sequences of β1A siRNA were:  sense strand, 5'-AUGGGACACGGGUGAAAAUTT-3'; 
antisense strand, 5'-AUUUUCACCCGUGUCCCAUTT-3'.  The sequences of β1C siRNA   were: 
sense strand, 5'-CCUCUGACUUCCAGAUUCCTT-3'; antisense strand, 5’-
GGAAUCUGGAAGUCAGAGGTT-3'.  siRNA duplexes were transfected using Oligofectamine 
(Invitrogen) at a final concentration of 20 nM.  After two rounds of transfection, cells were 
harvested 48 hrs post-transfection. 
 
Statistical Analysis 
 For immunofluorescence experiments detecting AR, p-Src, c-Src, or PSA, a total of 700 
cells were counted for each time point under different experimental conditions.  Each experiment 
was repeated three times.  The average and standard deviation values were calculated for every 
experiment.  Statistical analysis was performed pairwise using the Student’s t-test.  All p-values 
were based on two-tailed tests. 
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RESULTS 
Androgen Promotes Nuclear Localization of AR 
Steroid hormone receptors are ligand–activated transcription factors.  The intracellular 
movement and nucleo-cytoplasmic trafficking of steroid hormone receptors has been well 
researched, and the data indicate that unliganded receptor localizes in the cytoplasm as a 
heteromeric complex with heat shock proteins (Roy et al., 1999; Roy et al., 2001).  Upon ligand 
binding, the receptor undergoes conformational changes, homodimerization, nuclear 
translocation, and initiation of target gene expression.  AR is localized in the nucleus upon 
stimulation with dihydroxy-testosterone (DHT), and is exported back into the cytoplasm upon 
DHT withdrawal (Roy et al., 1999; Roy et al., 2001).  
In the first set of experiments of this thesis, the dynamic trafficking of AR in the LNCaP 
(AD) cell line was studied over a period of time under starvation and stimulation conditions. AR 
translocation was evident as soon as 15 minutes after stimulation with synthetic androgen R1881 
(Fig 8A), and accumulated in the nucleus after 2 hrs of stimulation with R1881.  Under 
starvation conditions, AR was predominantly localized in the cytoplasm (Fig 8B).  These results 
confirm the previously published data (Roy et al., 2001; Marcelli et al., 2006), and validate the 
androgen sensitivity of our LNCaP/R1881 system.  
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Fig 8 
(A)                
 
(B) 
 
Figure 8:  AR Nuclear Localization After R1881 Stimulation.  LNCaP (AD) cells were 
seeded on poly-L-Lysine (1 mg/ml)-coated cover-slips for two days.   Cells were starved 
for 24 hrs, then stimulated with R1881 (1 nM) (upper panel), or ethanol  (EtOH) (vehicle) 
(lower panel) for different time points.  Immunofluorescence was performed by staining 
the cells with anti-AR (N20).  Nuclear staining was performed using DAPI.  Pictures were 
taken at different time points as indicated. 
 
The AR nuclear export mechanism was also studied over a period of time.  Cells were 
stimulated for 2 hrs with R1881, then R1881 was removed.  Pictures were visualized using 
IPLab V3.55 at different time points (Fig 9).  It was found that AR localized in the nucleus after 
2 hrs of stimulation with R1881, but gradually started to move out from the nucleus after 
withdrawal of R1881.  At 2 hrs after the withdrawal of R1881, weak diffused cytoplasmic and 
nuclear AR staining patterns were observed.  Hence, I conclude that AR shuttles to and from the 
 29 
nucleus, and its movement depends upon androgen stimulation or withdrawal.  AR activity is 
known to be high in PrCa, which is a result of AR nuclear translocation.  In recurrent PrCa, AR 
activity is found high among patients exhibiting an androgen-independent phenotype (Feldman 
and Feldman 2001).  This androgen-independent AR activity can be the result of unmonitored 
AR activation through several co-factors, growth factors, integrins, or other signaling 
mechanisms. 
Fig 9 
 
Figure 9:  AR Dynamic Trafficking.  LNCaP (AD) cells were seeded on poly-L-Lysine 
(1 mg/ml)-coated cover-slips for two days.  Cells were starved for 24 hrs, then  
stimulated with R1881 (1 nM) for 2 hrs.  R1881 was removed and immunofluorescence 
was performed by staining cells with anti-AR (N20) at different time points as indicated.  
Nuclear staining was performed using DAPI.  Pictures were taken at different time 
points.  
 
Androgen Does Not Affect p-Src or c-Src Localization Based on Immunofluorescence  
AR cooperates with many co-factors, and recently Src was found to be an important co-
factor that affects AR activity in PrCa (Guo et al., 2006).  Src, which is known to be involved in 
tumor growth and metastasis in PrCa, affects AR translocation and activity in vitro (Gioeli et al., 
2002).  During in vivo studies, hormone-refractory PrCa tumor xenografts exhibited increased 
Src phosphorylation when compared with hormone-sensitive xenografts.  To confirm a definite 
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role of Src in the regulation of AR activity in PrCa, I investigated the effect of R1881 AR ligand 
on Src phosphorylation at stimulatory site Y416 (p-Src), and total cellular scr (c-Src) localization 
and expression in LNCaP (AD) and C4-2B (AI) PrCa cells in the presence and absence of 
R1881.  p-Src and c-Src were found to be localized in the cytoplasm as well in the nucleus 
irrespective of R1881 stimulation (Fig 10).  No statistically significant differences (p>0.05) were 
observed (Fig 10C).  Hence, I conclude that based on immunofluorescence, androgen 
stimulation does not affect p-Src or c-Src localization in PrCa cells. 
Fig 10                                                                             
(A) 
 
(B) 
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(C) 
 
Figure 10:  Based on Immunofluorescence Microscopy p-Src and c-Src Are Localized 
in the Cytoplasm and Nucleus Irrespective of Androgen Status.  LNCaP (AD) (Panel 
A) and C4-2B (AI) (Panel B) cells were seeded on poly-L-Lysine (1 mg/ml) coated cover-
slips for 2 days.  Cells were starved for 24 hrs, then stimulated with R1881 (1 nM) or 
ethanol (vehicle) for 15 min or 60 min.  Immunofluorescence was performed by staining 
cells with antibodies against c-Src or p-Src.  Nuclear staining was performed using DAPI.  
(Panel C) The graphs represent the mean of triplicates ± SD, while p values are based on 
three different experiments.  Error bars denote standard error. There were no statistically 
significant differences, p>0.05. 
 
Androgen Affects Src and AR Activation Based on Cell Fractionation 
Using sub-cellular fractionation, c-Src and p-Src expression levels were analyzed in the 
presence and absence of R1881.  R1881 stimulation increased p-Src levels in both LNCaP (AD) 
and C4-2B (AI) cells (Fig 11).  The localization of c-Src and p-Src were also studied under these 
conditions.  In agreement with the immunofluorescence results, R1881 stimulation did not affect 
the localization of total cellular c-Src when analyzed by cell fractionation.  c-Src was found in 
both cytoplasmic and nuclear fractions, independent of androgen status, in either AD or AI cell 
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lines.  In contrast to c-Src, the levels of p-Src clearly increased in the nucleus (and lesser so in 
the cytoplasm) after androgen stimulation, for either LNCaP cells (left panel, third row) or C4-
2B cells (right panel, top row), indicating that androgen affects Src activation in both cell lines.  
Fig 11 
 
 
Figure 11:  Nuclear Localization of Src and AR.  LNCaP (AD) and C4-2B (AI) cells 
were starved for 24 hrs using RPMI containing 2% CSS followed by stimulation with 
R1881 (1 nM) or ethanol for 24hrs. Cell lysates were subjected to fractionation, 
cytoplasmic and nuclear fractions were collected.  The collected fractions were subjected 
to immunoblotting (IB) using mAbs against AR (AR441), c-Src and α-tubulin (DM1A).   
pAbs were used against  p-Src (Y416), pS81-AR and RCC1 (C-20).  α-tubulin was used 
as a loading control for the cytoplasmic fractions.  RCC1 was used as a loading control 
for the nuclear fractions. C, cytoplasmic fraction; N, nuclear fraction. 
 
The cell fraction technique was also applied to AR.  AR was found to localize in the 
nucleus of LNCaP (AD) (Fig 11, left panel, second row; Fig 12A, top row) and C4-2B (AI) cells 
(Fig 12A, top row) upon stimulation with R1881 for 2 hrs, as compared with non-stimulated 
(vehicle treated) cells.  I also found that upon stimulation with R1881, pS81-AR (an AR site 
indirectly phosphorylated by Src) (Yang et al., 2009) also localizes in the nucleus of LNCaP 
cells (Fig 11, left panel, top row).  In addition, increased expression levels of AR were found in 
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the cytoplasmic fractions from vehicle treated cells as compared to cytoplasmic fractions from 
R1881 treated cells.  Therefore, it can be suggested that upon ligand binding AR becomes 
activated (p-AR) and localizes to the nucleus.  
The cell fractionation technique was also applied to PSA.  Translocation of AR from the 
cytoplasm into the nucleus is required for AR to exert its transcriptional activity (Heinlein and 
Chang 2004).  PSA is a gene strongly regulated by AR activity, therefore, I examined PSA levels 
in cytoplasmic and nuclear fractions in R1881 treated and untreated cells.  High PSA levels were 
found in nuclear and cytoplasmic fractions of R1881-treated LNCaP (AD) cells, and no 
expression of PSA was found in vehicle treatment (Fig 12A, left panel, second row).  In C4-2B 
(AI) cells, PSA was found in approximately equal amounts in nuclear and cytoplasmic fractions, 
in either androgen-stimulation or deprivation conditions (Fig 12A, right panel, second row).  
Immunofluorescence studies done for PSA localization in LNCaP (AD) and C4-2B (AI) cells 
upon androgen stimulation and deprivation revealed similar results as obtained by fractionation 
experiments (Fig 12B).  Overall, these data show that androgen stimulation activates Src (p-Src), 
increases nuclear levels of AR, and increases cellular levels of PSA.  The nuclear localization of 
PSA previously thought only to be a secretory protein is novel.  The nuclear co-localization of 
AR, Src, and PSA might play an important role in disease progression. 
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Fig 12A  
 
Fig 12B   
                                                                                                                                                                    
Figure 12:  AR and PSA Nuclear Translocation.  (A) LNCaP (AD) and C4-2B (AI) 
cells were starved for 24 hrs using RPMI containing 2% CSS, followed by stimulation 
with R1881 (1 nM) or ethanol for 24 hrs.  Cell lysates were subjected to fractionation, 
then cytoplasmic and nuclear fractions were collected.  The collected fractions were 
subjected to IB)using mAbs against AR (AR441) and α-tubulin (DM1A). (B) LNCaP 
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(AD) and C4-2B (AI) cells were seeded on poly-L-Lysine (1 mg/ml)-coated cover-slips 
for two days.   Cells were starved for 24 hrs and stimulated with R1881(1 nM) or ethanol 
(EtOH).  Immunofluorescence was carried out by staining cells with pAb against PSA.  
rIgG was used as a negative control for staining.  Nuclear staining was performed using 
DAPI. 
 
    
 
 Src Differentially Affects AR Activity in Androgen-Dependent and 
Independent PrCa Cell Lines 
 
 To study the effect of Src kinase on AR transactivation, transfection studies were 
performed in the LNCaP (AD) cell line using plasmids encoding wt-src or SrcK298M.  The 
plasmids were transiently transfected into LNCaP (AD) cells, and AR, PSA, and AKT levels 
were studied 72 hrs post-transfection.  I observed that there was no difference in expression 
levels of AR in cells transfected with SrcK298M plasmid compared to cells transfected with wt-
src (Fig 13, left panel).   
Fig 13 
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Figure 13: Src Differentially Affects AR Activity in AD and AI PrCa Cells.  LNCaP 
(AD) and C4-2B (AI) cells were transiently transfected with plasmids encoding wt-src or 
SrcK298M using Lipofectamine 2000 (Invitrogen).  Cell lysates were collected after 72 
hrs of transfection, and were subjected to IB using mAbs specific for AR (AR441) or c-
Src.  Primary Abs were used against p-Src (Y416), PSA, AKT1/2/3, or ERK1/2 (C16) 
(the latter was used as a loading control).  Dominant negative src inhibits AR activity 
(PSA levels) in AI PrCa cells, but has no effect on AR activity in AD PrCa cells.   
 
In addition to androgen signaling, which plays an important role in PrCa, the 
phosphotidylinositol 3-kinase (PI3K) pathway represents another important mechanism with 
roles in PrCa.  Kinase AKT modulates AR activity, which is cell-type and passage number-
dependent (Lin et al., 2003).  Therefore, AKT and PSA levels were analyzed.  In AD cells (Fig 
13, left panel), AKT levels were comparable in cells transfected with SrcK298M and wt-src, 
although a slight decrease in AKT was sometimes observed in SrcK298M samples.  Thus, in AD 
cells, dominant-negative src expression appears to have no strong effect on PSA or AKT levels.   
However, in C4-2B (AI) cells (Fig 13, right panel), SrcK298M transient transfection inhibited 
AR activity (as measured by PSA and AKT levels) compared to cells transfected with wt-src. 
Thus, dominant-negative src appears to down-regulate AR activity in the AI PrCa cell line, but 
not in the AD cell line.  Thus, we conclude that Src differentially affects AR activity in AD and 
AI PrCa cell lines. 
 
αvβ3 Integrin Increases Src Activation in a Ligand-Dependent Manner 
Integrins regulate Src-mediated oncogenic transformation and various aspects of 
morphological transformation through different pathways (Goel et al., 2008).  It has also been 
reported that αvβ3 integrin promotes anchorage-independence through Src-mediated pathways 
(Desgrosellier et al., 2009). The interaction of Src with αvβ3 integrin is required for tumor 
formation.  With respect to PrCa, integrin signalling may play a key role in the switch from early 
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stage AD tumors to later stage AI tumors (Goel et al., 2008).  Hence, I studied the integrin-Src 
pathway in PrCa cells using an integrin ligand-binding assay with LNCaP (AD) and C4-2B (AI) 
cell lines stably expressing αvβ3 integrin (Fig 14).  I found that transfection with αvβ3 integrin 
increases p-Src levels upon attachment to ligands fibronectin or TGFβ-LAP, as compared to 
control cell lines expressing αvβ6 integrin, in either AD (Fig 14 A) or AI (Fig 14B) cell lines.  
Therefore, I concluded that αvβ3 integrin increases p-Src levels in a ligand-dependent manner.   
Fig 14  
 (A)                                                      (B)  
 
          (C) 
 
Figure 14:  αvβ3 Integrin Increases Src Activation.  LNCaP (AD) (A) 
and C4-2B (AI) (B) cells were starved in serum-free culture medium for 
24 hrs before incubation with ligands fibronectin (FN) (3 mg/ml), LAP-
TGF-β (0.5 mg/ml), or BSA for 1 hr.  Cell lysates were collected and 
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subjected to IB using mAbs specific for c-Src.  Primary Abs were for c-
Src or p-Src (Y416). (C) LNCaP cells were transfected with β1A siRNA 
or NS siRNA using Oligofectamine (Invitrogen).  Cell lysates were 
collected 48 hrs post transfection and subjected to to IB using Abs 
specific for c-Src, p-Src (Y416), or β1A integrin. 
 
To prove integrin specificity of the observed effect, I also studied whether β1A integrin, 
which is endogenously expressed in many cell lines affects Src activation.  Therefore, I down-
regulated β1A integrin by siRNA in LNCaP (AD) cells, and found that inhibition of β1A integrin 
has no effect on Src activation as compared to the non-silencing control (Fig 14C).  Hence, we 
concluded that Src activation is integrin-specific and ligand-dependent. 
I also studied the effect of αvβ3 integrin on AR activity in both LNCaP (AD) and C4-2B 
(AI) cell lines (Fig 15).  I found that there was no apparent change in the total cellular levels of 
PSA or AKT as compared to mock transfected cells, although small changes in sub-cellular 
levels (i.e. in the nucleus) can not be ruled out.  In conclusion, although αvβ3 integrin when 
bound to ligand strongly activates p-Src, it does not appear to affect AR activity. 
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Fig 15 
 (A)                                                      (B)                                                      
 
   
Figure 15:  αvβ3 Integrin Does Not Affect PSA Expression Levels.  
LNCaP (A) or C4-2B (B) cells were tranfected with a plasmid encoding 
αvβ3 integrin, or were mock transfected.  Cell lysates were collected, 
and subjected to IB using Ab for PSA, p-Src (Y416), c-Src, or AKT 
(loading control).  
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DISCUSSION 
 
The purpose of this thesis was to analyze the role of Src in the regulation of AR activity, 
and to investigate a potential effect of αvβ3 integrin, a surface receptor known to be upregulated 
in PrCa (Goel et al., 2008), on AR activity through Src.  Src signaling plays an important role in 
PrCa progression.  Its inhibition has previously been shown to decrease tumor volume (Recchia 
et al., 2003).  It has also been shown that Src can interacts with AR to enhance AR 
transactivation.  Although it has been shown that Src can promote AR activity, the underlying 
pathway has not been defined, nor has it been shown whether Src activation of AR plays a role in 
integrin-Src signalling.  The novel findings described in this thesis show that the cytoplasmic 
tyrosine kinase Src (Martin, 2001) differentially affects AR activity, evaluated by measuring 
PSA levels, in AD and AI PrCa cells.  Specifically, Src was found to stimulate AR activity in AI 
cells but not in AD cells.  The results also show that Src, AR and PSA localize in the nucleus, 
suggesting a macromolecular interaction which could further enhance AR transactivation.  
Finally, I demonstrate that although αvβ3 integrin increases Src phosphorylation, its activation 
does not affect PSA levels mediated by AR. 
 
Src, AR, and PSA Localization 
The first set of investigations focused on studying the localization of Src, p-Src, AR, 
pAR, and PSA, in AD and AI cells, in the presence and absence of androgen.  Using sub-cellular 
fractionation, the data showed that treatment of AD cells with synthetic androgen R1881 
increased p-Src, AR, pAR, and PSA in the nucleus, while the levels of c-Src remained 
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unchanged.  Treatment of AI cells with R1881 increased pSrc and AR in the nucleus, while the 
levels of c-Src and PSA remained unchanged.  However, when using immunofluorescence 
microscopy, R1881 did not appear to increase the nuclear levels of p-Src or c-Src, so perhaps this 
technique is not as sensitive or quantitative as the sub-cellular fractionation/immunoblots.   
The increase in p-Src levels in PrCa cells treated with R1881 supports previously 
published work (Kraus et al., 2006).  The findings with the R1881-induced increase in nuclear 
AR make sense, since Src has previously been shown to promote the nuclear localization of 
various transcription factors, including AR and RUNX3, and AR nuclear import is crucial for its 
function as a DNA transcription factor (Guo et al., 2006; Cutress et al., 2008; Goh et al., 2010). 
 
PSA in the Nucleus 
While performing these studies, I unexpectedly found the AR target gene, PSA, in the 
nucleus of AD and AI PrCa cells, suggesting a possible role of PSA in gene transactivation.  
PSA has long been known to be a secreted protein that functions to prevent seminal fluid 
coagulation, but it is also known to promote cell growth (Niu et al., 2008).  Although its nuclear 
localization has not been reported, it was previously shown that PSA increases ARA70/AR-
mediated transactivation (Niu et al., 2008).  Thus, the nuclear localization of PSA may help 
define its specific role in PrCa progression.  With respect to cancer therapeutics, targeting PSA 
itself might be needed to stop PSA-induced PrCa progression.  Initial clinical studies with PSA-
encoding recombinant vaccinia vectors (rV-PSA) demonstrated safety and immunogenicity 
(Sanda et al., 1999; Gulley et al., 2002).  Phase I and II clinical trials with a PSA vaccine have 
shown a 44% reduction in the death rate, and an 8.5-month improvement in median overall 
survival in men with castration-resistant PrCa (Lubaroff et al., 2009; Kantoff et al., 2010).  Phase 
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III trials with PROSTVA are currently in progress.  These data suggest that targeting PSA will 
be a novel therapeutic strategy to treat patients with recurrent PrCa.  
 
Dominant-Negative Src Experiments 
Src signaling is involved in androgen-induced proliferation of PrCa cells (Migliaccio et 
al., 2000) and may also participate in the transition to AI growth (Lee et al., 2001; Lee et al., 
2004; Unni et al., 2004).  Src promotes AI growth and metastasis (Lee et al., 2004; Chang et al., 
2007).  Previous reports on Src kinase activity in PrCa cells show that constitutively active src 
increases AR transactivation, while dominant-negative src (in agreement with this thesis data) 
decreases AR transactivation in AI PrCa cells (Guo et al., 2006).  The Guo et al. study also 
showed that Src phosphorylates AR in AI-prostate cancer cells (Guo et al., 2006).  Consistent 
with these published data, I have shown that a dominant-negative variant of src (SrcK298M) 
prevents AR activity in C4-2B AI cells.  However, this effect is specific for AI cells, but is not 
observed in AD LNCaP cells.  In these latter cells, the Src dominant-negative variant does not 
prevent AR activity.  These results, may have profound implications in the strategy currently 
used in several clinical trials which are targeting Src in PrCa (Guarino, 2010).  It has been 
reported that dominant-negative src destroys the interaction of RACK1 (receptor for activated C 
kinase 1), AR, and Src (Kraus et al., 2006) in PrCa cells.   Therefore, the effect of Src in AI PrCa 
cells may be due to a differential expression of scaffolding proteins such as RACK1 that help 
bring kinase and substrate together (Kraus et al., 2006). 
 
Integrins and Src Activity 
The third and final purpose of this thesis was to investigate the potential effects of αvβ3 
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integrin on AR activity.  αvβ3 is a surface receptor previously shown to be upregulated in 
prostate cancer, through Src.  Integrins promote a wide-range of adhesion-dependent effects in 
tumor cells.  Most integrins activate FAK and thereby also other members of the Src Family 
Kinaes (SFK), which causes activation of several downstream pathways (Guo and Giancotti, 
2004).  Integrins bind ECM ligands, and act to couple cells to their microenvironments.   
Here I show that αvβ3 integrin increases Src activation in AD and AI PrCa cells.  
Previous reports show that αvβ3 integrin alters TGF-β  signaling in mesenchymal epithelial cells 
(MECs); the ability of TGF-β   to promote invasion is mediated by phosphorylation of TGFβ-
 receptor II   by Src kinase (Galliher and Schiemann, 2006).  I confirm that αvβ3 integrin, but not 
αvβ6 integrin, increases Src activation upon attachment to ligands fibronectin or TGFβ-LAP 
(Desgrosellier et al., 2009).  This shows that in addition to Src activation by androgens in AD 
cells, Src can also be activated by integrins in a ligand-dependent and integrin-specific manner.  
Since Src activation increases AR activity, I hypothesized that αvβ3 integrin can promote AR 
transactivation through Src.  Thus, I investigated the effect of αvβ3 integrin–mediated Src 
activation on PSA expression levels.  The findings show surprisingly that the αvβ3 integrin–Src 
pathway does not affect PSA expression levels.  Therefore, I concluded that the αvβ3 integrin–
Src signaling pathway is AR-independent, or that this pathway upregulates a different AR target 
gene.  Indeed, PSA is not the only AR target gene; other AR responsive genes include 
TMPRSS2, PRKCD (Protein kinase C delta), PYCR1 (Pyrroline-5-carboxylate reductase 1), and 
many others (Jariwala et al., 2007; Bolton et al., 2007).  Thus, potential increases in these other 
AR-responsive proteins should be analyzed in integrin-transfected cells to help determine 
whether AR participates in the integrin-Src pathway. Studying the integrin-mediated changes in 
the expression levels of these genes, and other genes known to be activated by Src, will likely 
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bring new insights in the mechanisms underlying the integrin-Src pathway. 
 
OVERALL CONCLUSIONS 
 
From the present study I conclude that Src is required for AR activity and, consequently, 
PSA expression in androgen-independent prostate cancer cells, but not in androgen-dependent 
cells.  The findings in this thesis of the nuclear co-localization of p-Src, AR, and PSA appears to 
be consistent with their roles in disease progression.  Given PSA’s ability to induce cell division 
and decrease apoptosis when transfected into cells, its presence in the nucleus as first shown in 
this thesis may imply that PSA acts there to help induce tumorigenesis.  With respect to 
integrins, cells transfected with αvβ3 but not αvβ6 increase Src activity, although the increased 
Src activity  does not appear to affect AR transactivation.  
Therefore, during integrin-Src signaling, which likely increases in the AI state, perhaps 
other AR-genes are involved, or other pathways besides AR helps maintain the tumorigenesis. 
 
 
FUTURE EXPERIMENTS 
 The present investigation can be extended for future studies as follows:  
1. Analyze a potential role of PSA in promoting PrCa progression. The experimental design 
could include: inhibiting or over-expressing PSA in LNCaP (AD) and C4-2B (AI) cell lines, and 
studying changes in gene expression, cell adhesion, cell migration, and cell viability.  Analyzing 
the type of integrin expression at the cell surface by down-regulating or over-expressing PSA 
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could further help define the integrins that affect the PSA-AR pathway.  
  
2. Analyze a potential interaction between Src kinase and PSA in PrCa cells.  To study a 
possible interaction of Src-AR-PSA in PrCa cells, immunoprecipitation of PSA followed by 
immunoblotting with Src, and vice versa, will be required to confirm the interaction.  This 
potential interaction can further unfold the mechanism behind nuclear localization of Src, AR 
and PSA.  This interaction could also be investigated in an integrin-dependent environment to 
help define the specific integrin-Src-AR-PSA pathway in PrCa.  
  
3. Study the downstream effects resulting from αvβ3 integrin-Src activation.  To analyze the 
αvβ3 integrin-Src pathway in PrCa, hybridization arrays could be used to help identify specific 
genes up- or down-regulated by this pathway.  RNA could be isolated from cells transfected with 
various integrins, with or without co-transfection with the Src dominant-negative plasmid, to 
hybridize to commercial arrays.  It could be suggested that the αvβ3 integrin–Src signaling 
pathway is AR-independent, so this approach could help identify genes important to PrCa 
progression in an androgen-independent and AR-independent state.  Candidates identified by 
arrays could be confirmed by RT-PCR.  Further studies at RNA (RT-PCR) and DNA level 
(CHIP analysis) could determine the requirement of AR and its target gene to regulate gene 
transcription. 
  
4. All of the above studies could be extended to PrCa mouse models in vivo to confirm the in 
vitro findings. 
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